ArticleClinical & experimental metastasis2026
Mitochondrial transcript abundance in breast cancer circulating tumour cells may reflect both blood-derived transcripts and biological heterogeneity.
Article in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Circulating tumour cells (CTCs) are rare cells frequently profiled on a single cell level. A key indicator of single-cell transcriptome quality is the percentage of reads encoded by genes in the mitochondrial genome (MT-reads). No systematic data exists on MT-reads content in CTCs, making it unclear whether this parameter can reliably indicate CTCs' transcriptome quality. We collected RNA-Seq profiles of 349 single breast cancer (BC) CTCs and 129 white blood cells (WBCs) enriched with four methods to assess the level of MT-reads and the expression of markers of the most abundant blood components-red blood cells (RBCs) and platelets (PLTs). The median percentage of PLTs and RBCs transcripts in CTCs was 2% (0-38%) and 0.8% (0.0006-84%), respectively, with significant differences between enrichment methods (p < 2.2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.